Prokarium, a clinical-stage biopharmaceutical company pioneering the field of microbial immunotherapy, has appointed Ibs Mahmood as Chief Executive Officer (CEO).

Mahmood succeeds Kristen Albright, who will join the Board of Directors to continue shaping Prokarium’s strategic direction.

Mahmood brings 25 years as a biotechnology entrepreneur having founded and led multiple life science companies through clinical development, financing and strategic transactions, raising more than $300 million for his own ventures and over $2 billion for clients. He previously co-founded and led AMO Pharma, DrugDev and Induction Healthcare, and enjoyed senior roles at IQVIA, Abingworth, Shire Pharma and Investec.

“Ibs’ appointment marks an important step in Prokarium’s evolution. His unique blend of medical insight, entrepreneurial drive and industry experience will help us accelerate our mission to change the treatment paradigm in bladder cancer,” said Ted Fjällman, Chairman of Prokarium’s Board of Directors. “With strong clinical momentum and a clear vision for transforming bladder cancer treatment, Prokarium is well positioned for the future.”

Mahmood said, “Prokarium is redefining how we treat bladder cancer, using microbial immunotherapy to activate the immune system in ways traditional approaches cannot. I am excited to join the team as we continue to advance through clinical milestones to shift the standard of care.”